Open-label Follow-up Study of the PEPITES Study to Evaluate the Long-term Efficacy and Safety of Viaskin Peanut
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 08 Jan 2018
At a glance
- Drugs Peanut allergy immunotherapy (Primary)
- Indications Peanut hypersensitivity
- Focus Adverse reactions; Therapeutic Use
- Acronyms PEOPLE
- Sponsors DBV Technologies
- 07 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 23 Jan 2017 Status changed from not yet recruiting to recruiting.
- 10 Jan 2017 New trial record